Does this mean the components interfere with each other?

It means there is a specific mechanism by which two of them could, which nobody has tested. Stating an untested possibility as a finding would be exactly the error this library exists to avoid.

Would the copper stop GHK-Cu being transported?

It might. A chelated metal ion changes the molecule's dimensions and charge distribution substantially, and transporters are sensitive to both. Whether GHK-Cu, free GHK, or neither is a substrate is unresolved in the literature reviewed here.

Is PepT1 relevant if the blend is not taken orally?

PepT1 is best characterised in intestinal epithelium, which is why oral exposure is where it matters most. Nothing here concerns administration of any kind - this is a statement about a transporter's substrate range and about which molecules fall inside it.

Why does the charge preference matter?

Because it sets which peptides the transporter handles well at the pH it normally works at. Two basic tripeptides in one vial are competing, if at all, within the category the transporter is least efficient at - which would make any competition between them more consequential, not less.

KLOW (Blend)

Half of This Blend Is Small Enough to Share a Route

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-245 cited sources

Two of KLOW's four components are tripeptides, and one of them - KPV - is a demonstrated substrate of the di- and tripeptide transporter PepT1. Whether the other tripeptide competes for the same carrier is an obvious question with no published answer.

Key facts

Tripeptides in the blend: 2 of 4 - KPV and GHK
KPV sequence: Lys-Pro-Val
GHK sequence: Gly-His-Lys
Transporter: PepT1, gene SLC15A1
KPV as PepT1 substrate: Demonstrated by competition, labelled uptake and knockout
GHK as PepT1 substrate: Not established in the literature reviewed here
PepT1 charge preference: Neutral and acidic peptides at physiological pH
Both blend tripeptides: Basic

Why size sorts this blend into two halves

PepT1 carries di- and tripeptides. That is its defined substrate range, and it is a strict one: the transporter does not carry free amino acids and it does not carry peptides of four residues or more. Applied to KLOW, that draws a line straight through the middle of the vial. KPV is three residues and GHK is three residues, so both fall inside the range. TB-500 as supplied is an acetylated heptapeptide and BPC-157 is fifteen residues, so both fall well outside it. Whatever route the larger two take, it is not this one.

What is established for KPV

More than for most compounds in this library. Dalmasso and colleagues demonstrated PepT1-mediated uptake of KPV using unlabelled KPV as a competitor against a radiolabelled PepT1 substrate and tritiated KPV to determine its own transport kinetics, in human intestinal epithelial and T-cell lines. Viennois and colleagues then showed that in PepT1-knockout mice, KPV produced none of the effect it produced in wild-type animals. Competition, direct labelled uptake and a genetic knockout is a complete set, and it makes KPV's status as a PepT1 substrate about as well supported as such things get.

Research material referenced

KLOW 80mg — third-party HPLC tested

View — £69.99

What is not established for GHK

Whether it is a substrate at all. GHK is Gly-His-Lys, a tripeptide, and PepT1 has broad specificity - it recognises general structural features rather than particular sequences, which is why it carries thousands of possible di- and tripeptides and a range of peptidomimetic drugs never designed for it. On that basis GHK is a reasonable candidate. But candidacy is not demonstration, no work reviewed here tests it, and the copper complex adds a complication: GHK-Cu is not GHK, and a chelated cupric ion changes the molecule's size, charge and shape in ways a transporter would notice.

The charge point, which cuts against both

Steel and colleagues characterised PepT1's stoichiometry and pH dependence and found that at physiological external pH - around 5.5 to 6.0 at the brush border - the transporter prefers neutral and acidic peptides. Basic dipeptides had their transport maxima shifted to higher pH, which the authors suggest may involve titration of a side chain on the transporter itself. KPV carries a lysine and GHK carries both a histidine and a lysine, so both are basic peptides and both sit in the class the transporter handles least favourably at the pH where it normally operates. That does not make KPV a non-substrate - it demonstrably is one - but it does mean the two tripeptides here are competing, if they compete at all, in the same disfavoured charge category.

Why the question is worth asking of a blend specifically

Two compounds administered separately do not compete for a transporter in any meaningful sense unless they happen to be present together. A co-formulation guarantees they are. If both tripeptides in this vial are PepT1 substrates, then the amount of either that crosses depends on how much of the other is present - which makes the blend's behaviour a function of its ratio in a way that has nothing to do with pharmacology at the target and everything to do with a shared carrier. That is the most concrete mechanistic reason to want the per-component split stated, and it is a question no work on this combination has addressed because no work on this combination exists.

What is and is not being claimed

That KPV is a PepT1 substrate is published and well controlled. That GHK is a tripeptide is a structural fact. That PepT1 prefers neutral and acidic peptides at physiological pH is published. Everything joining those together into a statement about what happens in a vial containing both is a question, written here as a question. No published work addresses this combination in any respect, and nothing here describes what any compound does in a person. All four components are supplied for laboratory research only.

Quick reference

Component	Residues	In PepT1's substrate range	Established as a substrate
KPV	3	Yes	Yes - competition, labelled uptake, knockout
GHK-Cu	3 plus a chelated copper ion	By size, yes	Not established
TB-500	7, acetylated	No	No
BPC-157	15	No	No

Extended research context

The KLOW (Blend) deep dive

Deep dive: a fourfold size range in one cake, and what partial dissolution hides

KLOW's components run from KPV at 342.43 daltons to BPC-157 at 1419.5 - a fourfold span, and the widest of any product in this catalogue. Solubility depends on size, charge distribution and hydrophobicity, and these four differ in all three, so a co-lyophilised cake containing all of them releases its components in sequence rather than together. The hazard follows directly and is easy to miss: a cake that looks partly dissolved is not uniformly partly dissolved. The smallest component may be entirely in solution while the largest has barely started. Draw from the vial at that moment and the sample is enriched in the fast components and depleted in the slow ones - a composition error with no visible sign at all, since the liquid looks like liquid. The instinctive response to visible solid makes it worse: shaking creates air-liquid interfaces, which is exactly where peptides unfold and then aggregate irreversibly. The correct response is diluent down the vial wall, gentle swirling, and more patience than a single peptide or even a three-component blend requires. There is a second asymmetry on top. Small peptides adsorb to glass and plastic more readily than large ones, so KPV is the component most likely to be lost to container walls at low concentration - a silent shift in the effective ratio that no certificate figure accounts for.

Deep dive: the cleanest possible comparison, which still cannot be run

KLOW is a strict superset of GLOW - the same three components plus KPV, at 80 mg against 70 mg. Product comparisons rarely have this structure. There is nothing in GLOW that KLOW lacks, so the difference between them reduces to a single question rather than a balance of trade-offs, and in principle comparing the two would isolate exactly what KPV contributes. In practice it cannot be done. The 10 mg difference in total might be 10 mg of added KPV with the other three unchanged, or it might be a redistribution across all four; both are consistent with the published figures, and neither product states its split. So any difference observed between the two could be KPV, or it could be a changed concentration of GHK-Cu, BPC-157 or TB-500. The experiment that the product pairing seems designed to permit is precisely the one the missing information forbids. This is the fixed-ratio limitation in its sharpest form: not that the format is unhelpful in general, but that it withholds the one number that would make the most natural question answerable.

Deep dive: two products from one hormone, in categories that never mention each other

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, isolated because that hormone does two functionally separable things - pigmentation through melanocortin receptors, and anti-inflammatory activity localised to its C-terminal end. KPV keeps the second and discards the first. Now look elsewhere in this catalogue: MT-2 is also an alpha-MSH derivative, and it is built around the melanocortin-receptor-binding core that KPV was specifically designed to leave behind. Two products, one parent hormone, opposite halves of its function, sitting in entirely separate product categories with nothing in either listing to indicate they are related. The size difference tracks the design logic. KPV at 342.43 daltons is three residues with no modifications, because an effect running through diffuse intracellular signalling can survive extreme truncation. MT-2 at 1024.2 daltons is seven residues plus a lactam bridge, a D-amino acid and two capped termini, because receptor engagement requires enough structure to present a specific surface. What a fragment needs to be depends entirely on what the retained function requires, and these two are as clean an illustration of that as this catalogue contains.

Research applications

▸Multi-component connective tissue research protocols
▸Comparative work on three-component versus four-component combinations
▸Co-lyophilisation and multi-component dissolution methodology
▸Copper peptide compatibility studies
▸Surface adsorption behaviour across a wide molecular size range
▸Anti-inflammatory and matrix pathway research

Handling checklist

✓Verify KPV as Lys-Pro-Val at 342.43 Da, CID 125672 - never by searching 'KPV'
✓Verify GHK-Cu against 402.92 Da (CID 71587328), not 340.38 for free GHK
✓Verify TB-500 against 889.0 Da, not 4.9 kDa for thymosin beta-4
✓Verify BPC-157 against 1419.5 Da
✓Expect four separate certifications - a single combined purity figure is a category error
✓Allow more dissolution time than a three-component blend; do not draw before it completes
✓Use low-binding consumables - KPV is the component most lost to surfaces
✓Store lyophilised, cold, dry and dark; the copper complex governs light protection

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Drawing from a partly dissolved four-component cake

Fix: Components dissolve in sequence across a fourfold size range. An early sample is enriched in fast components and depleted in slow ones, with no visible sign.

✗ Verifying the KPV component by searching 'KPV' in PubChem

Fix: That returns 2-oxo-5-phenylpentanoic acid at 192.21 Da, an unrelated compound. Search Lys-Pro-Val for CID 125672.

✗ Assuming the 10mg difference from GLOW is 10mg of KPV

Fix: Not stated. It could be added KPV with the others unchanged, or a redistribution across all four.

✗ Treating four component literatures as evidence about the blend

Fix: No published work addresses this combination or any subset of it. Summing separate literatures produces no evidence about a mixture.

✗ Adding a chelator because the blend contains copper

Fix: Unnecessary. None of the four components contains cysteine or methionine, so copper-catalysed oxidation has no substrate here.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Does this mean the components interfere with each other?: It means there is a specific mechanism by which two of them could, which nobody has tested. Stating an untested possibility as a finding would be exactly the error this library exists to avoid.
Would the copper stop GHK-Cu being transported?: It might. A chelated metal ion changes the molecule's dimensions and charge distribution substantially, and transporters are sensitive to both. Whether GHK-Cu, free GHK, or neither is a substrate is unresolved in the literature reviewed here.
Is PepT1 relevant if the blend is not taken orally?: PepT1 is best characterised in intestinal epithelium, which is why oral exposure is where it matters most. Nothing here concerns administration of any kind - this is a statement about a transporter's substrate range and about which molecules fall inside it.
Why does the charge preference matter?: Because it sets which peptides the transporter handles well at the pH it normally works at. Two basic tripeptides in one vial are competing, if at all, within the category the transporter is least efficient at - which would make any competition between them more consequential, not less.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More KLOW (Blend) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum